Abbott Laboratories Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Abbott Laboratories on November 16, 2016. The report addresses Item 8.01 (Other Events) regarding a definitive Agreement and Plan of Merger announced on April 26, 2016, for the acquisition of St. Jude Medical, Inc.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Abbott Laboratories. Instead, it incorporates by reference the financial statements of the target company, St. Jude Medical, as Exhibits 99.1 and 99.2. These exhibits contain:
- Consolidated balance sheets of St. Jude Medical as of January 2, 2016, and January 3, 2015.
- Consolidated statements of earnings, comprehensive income, shareholders' equity, and cash flows for the years ended January 2, 2016, January 3, 2015, and December 28, 2013.
- Condensed consolidated balance sheets of St. Jude Medical as of October 1, 2016, and January 2, 2016.
- Condensed consolidated statements of earnings, comprehensive income, and cash flows for the nine months ended October 1, 2016, and October 3, 2015.
Material Changes
The primary material event is the progression of the acquisition of St. Jude Medical. The filing updates the record with recent financial data for St. Jude Medical through October 1, 2016, which is necessary for the merger transaction. No material changes to Abbott's standalone operations are detailed in this specific text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, or specific risk factors related to the transaction beyond the disclosure of the merger agreement itself. The document serves primarily to attach the required financial statements of the acquired business under Rule 3-05 of Regulation S-X.
Investor Verification Checklist
- Review Exhibit 99.1 for St. Jude Medical's audited financial statements for fiscal years 2013, 2015, and 2016.
- Review Exhibit 99.2 for St. Jude Medical's unaudited condensed financial statements for the nine months ended October 1, 2016.
- Verify the terms of the definitive Agreement and Plan of Merger announced on April 26, 2016.
- Confirm the status of regulatory approvals required to close the acquisition.